Evidence map›Paper›PMID 40401973›Full record

ArticleMicrobiology spectrum2025

Nalidixic acid-a good marker of fluoroquinolone resistance mechanisms in

Sofia Kalinen, Heini Kallio, Teemu Kallonen, Juha Knaapila, Tarja Lamminen, Pentti Huovinen, Peter Boström, Antti J Hakanen, Marianne Gunell

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sofia Kalinen *Institute of Biomedicine, University of Turku, Turku, Finland.
Heini Kallio *Institute of Biomedicine, University of Turku, Turku, Finland.
Teemu KallonenDepartment of Clinical Microbiology, Turku Clinical Microbiome Bank, Turku University Hospital, Turku, Finland.
Juha KnaapilaDepartment of Urology, Turku University Hospital, Turku, Finland.
Tarja LamminenDepartment of Urology, Turku University Hospital, Turku, Finland.
Pentti HuovinenInstitute of Biomedicine, University of Turku, Turku, Finland.
Peter BoströmDepartment of Urology, Turku University Hospital, Turku, Finland.
Antti J HakanenInstitute of Biomedicine, University of Turku, Turku, Finland.
Marianne GunellInstitute of Biomedicine, University of Turku, Turku, Finland.ORCID 0000-0002-4347-3233

Funding

Cancer foundation FinlandFinnish Governmental Special FundingSigrid Juséliuksen Säätiö (Sigrid Jusélius Stiftelse)Turku Combined Research FundingTurku University hospital foundation
6 · The paper itself

Abstract

The purpose of this study was to evaluate how ciprofloxacin, pefloxacin, and nalidixic acid disks perform in screening fluoroquinolone resistance mechanisms in 278 IMPORTANCE: We show in our clinical setting that fluoroquinolone resistance mechanisms are discovered, even among phenotypically fluoroquinolone-susceptible

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialEscherichia coliFluoroquinolonesNalidixic AcidCiprofloxacinDNA GyraseDNA Topoisomerase IVEscherichia coli InfectionsEscherichia coli ProteinsHumansMicrobial Sensitivity TestsMutationPefloxacinPlasmidsProspective StudiesAnti-Bacterial AgentsCiprofloxacinDNA GyraseDNA Topoisomerase IVEscherichia coli ProteinsFluoroquinolonesNalidixic AcidPefloxacinciprofloxacindrug resistance mechanismsEscherichia colifluoroquinolonenalidixic acidpefloxacin

Identifiers

PMID40401973
PMCPMC12211035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.